Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent

Print

Type 2 diabetes accounts for up to 95% of all cases of diabetes.
 
«Back | Next»

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development